Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Cognitivism01:17

Cognitivism

Cognitive psychology emerged as a significant field in the mid-20th century. It focused on understanding humans' internal mental processes. This approach emphasizes how people perceive, remember, think, and solve problems—elements critical to human cognition.
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process information is...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
Behavioral Genetics and Its Designs01:23

Behavioral Genetics and Its Designs

Behavior genetics explores how genetic inheritance influences human behavior. It focuses on how genes, passed from parents to offspring, contribute to the development of behavioral traits and tendencies. This branch of genetics seeks to understand the complex interplay between inherited genetic factors and environmental influences in shaping our behaviors.
The primary methodologies used in behavior genetics include family studies, twin studies, and adoption studies, each providing unique...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Brain Computed Tomography Attenuation Values Between Deep-Learning and Conventional Reconstruction Methods: A Bias-Free Approach.

Journal of computer assisted tomography·2026
Same author

Dynamic blebbing and absence of organelle transfer during mouse oocyte formation.

The EMBO journal·2026
Same author

Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease.

Nature medicine·2026
Same author

Salivary total tau: a clinically practical measure of tau neuropathology in Alzheimer's disease.

Journal of neurology·2026
Same author

Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA).

Neurology and therapy·2026
Same author

Handling Missing Data in Participants with Baseline but No Post-Baseline Data.

Pharmaceutical statistics·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Measuring Attention and Visual Processing Speed by Model-based Analysis of Temporal-order Judgments
13:00

Measuring Attention and Visual Processing Speed by Model-based Analysis of Temporal-order Judgments

Published on: January 23, 2017

Hierarchical Bayesian cognitive processing models to analyze clinical trial data.

William R Shankle1, Junko Hara, Tushar Mangrola

  • 1Shankle Clinic, Newport Beach, CA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|November 6, 2012
PubMed
Summary
This summary is machine-generated.

Hierarchical Bayesian analysis with cognitive processing (HBCP) models detected a harmful treatment effect in early Alzheimer's disease (AD) trials, unlike standard methods. This sensitive approach identifies subtle cognitive changes and treatment impacts in small patient samples.

More Related Videos

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

Online Repetitive Transcranial Magnetic Stimulation of Dorsomedial and Dorsolateral Prefrontal Cortex in Cognition Decision Making, and Cognitive Dissonance
13:20

Online Repetitive Transcranial Magnetic Stimulation of Dorsomedial and Dorsolateral Prefrontal Cortex in Cognition Decision Making, and Cognitive Dissonance

Published on: December 5, 2025

Related Experiment Videos

Last Updated: May 17, 2026

Measuring Attention and Visual Processing Speed by Model-based Analysis of Temporal-order Judgments
13:00

Measuring Attention and Visual Processing Speed by Model-based Analysis of Temporal-order Judgments

Published on: January 23, 2017

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

Online Repetitive Transcranial Magnetic Stimulation of Dorsomedial and Dorsolateral Prefrontal Cortex in Cognition Decision Making, and Cognitive Dissonance
13:20

Online Repetitive Transcranial Magnetic Stimulation of Dorsomedial and Dorsolateral Prefrontal Cortex in Cognition Decision Making, and Cognitive Dissonance

Published on: December 5, 2025

Area of Science:

  • Neuroscience
  • Clinical Trials
  • Biostatistics

Background:

  • Early detection of Alzheimer's disease (AD) treatment effects is crucial for drug development.
  • Subtle cognitive changes in early AD necessitate sensitive analytical methods for clinical trials.
  • Current FDA-required analytical methods may lack the sensitivity to detect early treatment effects.

Purpose of the Study:

  • To evaluate the sensitivity of hierarchical Bayesian analysis with cognitive processing (HBCP) models in detecting treatment effects in early Alzheimer's disease.
  • To compare HBCP model performance against standard analytical methods using data from a Phase III clinical trial.
  • To determine if HBCP models can identify treatment effects in small patient samples.

Main Methods:

  • Application of hierarchical Bayesian analysis with cognitive processing (HBCP) models.
  • Analysis of Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and MCI Screen word list memory task data.
  • Comparison of HBCP analysis with original analytical methods on both full and small patient samples.

Main Results:

  • HBCP models detected impaired memory storage during delayed recall, which standard ADAS-Cog analysis did not.
  • HBCP analysis identified a harmful treatment effect in a small sample, later independently confirmed.
  • Standard analytical methods failed to detect this harmful effect in both full and small samples.

Conclusions:

  • HBCP models demonstrate superior sensitivity in detecting treatment effects compared to current FDA-required methods.
  • HBCP models are effective in identifying subtle cognitive changes and treatment impacts even with small patient cohorts.
  • The findings suggest HBCP models could enhance early-stage Alzheimer's disease clinical trial design and analysis.